Effects of atorvastatin on systemic and renal nitric oxide in healthy man.
Statin treatment improves endothelial function but the effects of statins on renal nitric oxide have not been clarified. In this crossover study, 26 healthy subjects received atorvastatin 80 mg per day or placebo for 5 days. After 5 days of treatment, L-N(G)-monomethyl arginine caused a similar increase in blood pressure and decrease in urine output and glomerular filtration rate. The decrease in fractional excretion of sodium to L-N(G)-monomethyl arginine was more pronounced after atorvastatin treatment. Atorvastatin did not change the response to several vasoactive hormones. The results indicate that atorvastatin increase renal nitric oxide, which may explain a part of the pleiotropic effects of statins.
Department of Medical Research, Holstebro Hospital, Holstebro, Denmark. frchri@rm.dk
Frank Holden
FH
Mose
Thomas
T
Larsen
Jesper Noergaard
JN
Bech
Erling Bjerregaard
EB
Pedersen
D000293:Adolescent; D000328:Adult; D051399:Aquaporin 2 / Q000652:urine; D001120:Arginine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000069059:Atorvastatin; D001783:Blood Flow Velocity / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D018592:Cross-Over Studies; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006728:Hormones / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D008055:Lipids / Q000097:blood; D008297:Male; D009569:Nitric Oxide / Q000097:blood* / Q000652:urine*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D010919:Placebos; D011188:Potassium / Q000097:blood / Q000652:urine; D011673:Pulsatile Flow / Q000187:drug effects; D011758:Pyrroles / Q000008:administration & dosage*; D012084:Renin-Angiotensin System / Q000187:drug effects*; D012965:Sodium Chloride / Q000097:blood / Q000652:urine; D059289:Vascular Stiffness / Q000187:drug effects; D055815:Young Adult; D019323:omega-N-Methylarginine
D051399:Aquaporin 2; D001120:Arginine; D000069059:Atorvastatin; D006538:Heptanoic Acids; D006728:Hormones; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D010919:Placebos; D011188:Potassium; D011758:Pyrroles; D012965:Sodium Chloride; C496023:AQP2 protein, human; C092506:N(G)-monomethylarginine acetate; D019323:omega-N-Methylarginine